MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2022007475

Медицинская библиотека · Blood advances · 2022

Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.

Ferreri Andrés J M, Angelillo Piera, Erbella Federico, Cattaneo Chiara, Verga Luisa, Lleshi Arben, Allione Bernardino, Ponzoni Maurilio, Facchetti Fabio, Pagani Chiara, Foppoli Marco, Pecciarini Lorenza, Sassone Marianna, Steffanoni Sara, Flospergher Elena, Rossi Giuseppe, Spina Michele, Re Alessandro

СтатьяПеревод в очереди

Аннотация

Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with Burkitt lymphoma ([BL] n = 46) or high-grade B-cell lymphoma ([HGBCL] single, double, or triple hit; n = 22) were treated with a dose-dense, short-term therapy termed "CARMEN regimen" at 5 Italian centers. Forty-six (68%) patients were HIV+. CARMEN included a 36-day induction with sequential, single weekly doses of cyclophosphamide, vincristine, rituximab, methotrexate, etoposide, and doxorubicin plus intrathecal chemotherapy, followed by high-dose-cytarabine-based consolidation. Patients who did not achieve complete remission (CR) after induction received BEAM (carmustina, etoposide, cytarabine, melfalan)-conditioned autologous stem cell transplantation (ASCT) after consolidation. Sixty-one (90%) patients completed induction, and 59 (87%) completed consolidation. Seventeen patients received ASCT. Grade 4 hematological toxicity was common but did not cause treatment discontinuation; grade 4 nonhematological toxicity was recorded in 11 (16%) patients, with grade 4 infections in 6 (9%). Six (9%) patients died of toxicity (sepsis in 4, COVID-19, acute respiratory distress syndrome). CR rate after the whole treatment was 73% (95% confidence interval [CI], 55% to 91%) for patients with HGBCL and 78% (95% CI, 66% to 90%) for patients with BL. At a median follow-up of 65 (interquartile range, 40-109) months, 48 patients remain event free, with a 5-year progression-free survival of 63% (95% CI, 58% to 68%) for HGBCL and 72% (95% CI, 71% to 73%) for BL, with a 5-year overall survival (OS) of 63% (95% CI, 58% to 68%) and 76% (95% CI, 75% to 77%), respectively. HIV seropositivity did not have a detrimental effect on outcome. This retrospective study shows that CARMEN is a safe and active regimen both in HIV-negative and -positive patients with MYC-rearranged lymphomas. Encouraging survival figures, attained with a single dose of doxorubicin and cyclophosphamide, deserve further investigation in HGBCL and other aggressive lymphomas.

Для цитирования: Ferreri Andrés J M, Angelillo Piera, Erbella Federico, Cattaneo Chiara, Verga Luisa, Lleshi Arben, Allione Bernardino, Ponzoni Maurilio, Facchetti Fabio, Pagani Chiara, Foppoli Marco, Pecciarini Lorenza, Sassone Marianna, Steffanoni Sara, Flospergher Elena, Rossi Giuseppe, Spina Michele, Re Alessandro. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma.. Blood advances. 2022. DOI: 10.1182/bloodadvances.2022007475.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.